Claritus Pharmaceuticals Inc. (CLAZF)

[onedayyyyyyyyy]

It’ll be a lot higher than $.30 ,’...
Kalytera Announces Initiation of Research Coverage by Echelo
Kalytera Announces Initiation of Research Coverage by Echelon Wealth Partners
15 Jan 2019 07:29 ET
GlobeNewswire
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") announced that Echelon Wealth Partners, Inc. ("Echelon") has initiated research coverage on Kalytera with a speculative "Buy" rating and a one-year price target of $0.30 per share. The Company is pleased with the report and the recommendation, but emphasizes that the views expressed in the report are those of Echelon alone.

Echelon is a leading, independent Canadian-owned and operated wealth management and capital markets firm. Distribution and reproduction of the research report in any form is solely at the discretion of Echelon.

About Kalytera Therapeutics

Kalytera Therapeutics, Inc. is pioneering the development of CBD therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on GVHD and treatment of acute and chronic pain.

-- Website Home: https://kalytera.co/

-- News and Insights: https://kalytera.co/news/

-- Investors: https://kalytera.co/investors/


Read more at http://www.stockhouse.com/companies/bullboard#b8y508siXZpQSz08.99